ETNB News and Press, 89bio Inc. From 09/21/23

2023-09-21 08:53:15 ET More on 89bio Seeking Alpha’s Quant Rating on 89bio Historical earnings data for 89bio Financial information for 89bio 89bio, Inc.: A Big Bet On NASH 89bio gains as UBS starts at Buy; cites upcoming data from Akero ...

–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the fourth quarter of 2023– SAN FRANCISCO, Sept. 21, 2023 (GL...

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Man...

SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Mana...

2023-08-28 12:36:36 ET More on Akero, 89bio, etc. Akero Therapeutics: An Assessment 89bio, Inc.: A Big Bet On NASH Akero Therapeutics: Marching On And Delivering Promising Results Akero gains 15% on potential of liver disease drug and weight loss therapy comb...

2023-08-24 07:41:04 ET Summary Akero Therapeutics is a biopharmaceutical company focused on developing therapies for nonalcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease that can lead to liver failure and other serious health complication...

2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...

2023-08-10 13:48:08 ET Summary 89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-line data from a Phase 2 study for its primary drug candidate targeting NASH came out in March. Th...

2023-08-09 17:34:49 ET 89bio press release ( NASDAQ: ETNB ): Q2 GAAP EPS of -$0.52 misses by $0.11 . As of June 30, 2023, 89bio had cash, cash equivalents and short-term available-for-sale securities totaling $478.0 million. For further details see: 89bio GAA...

– Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress – – Discussions with regulatory agencies regarding Phase 3 NASH program...